Bristol-Myers Squibb and AbbVie have picked up another FDA approval for their multiple myeloma drug Empliciti that they hope will help drive uptake of the drug.
Bristol-Myers Squibb has broadened a collaboration with Infinity Pharmaceuticals as it seeks to find combinations that boost the potency of its cancer immunotherapy, Opdivo.
Bristol-Myers Squibb’s Opdivo and Yervoy combination could become first line treatment for a small group of metastatic colorectal cancer patients with aggressive tumours, on the basis of da
Merck & Co is to request licences for its Keytruda immunotherapy in kidney cancer, following trial results showing that it improved survival in combination with Pfizer’s Inlyta compared
Bristol-Myers Squibb has said its Opdivo immunotherapy has failed to improve on standard of care in patients with small cell lung cancer, who had relapsed following platinum-based chemother
